At Medlab Middle East 2021, Becton, Dickinson and Company (BD), a medical technology firm that manufactures medical devices, instrument systems, and reagents, highlighted its BD Biosciences business and BD Life Sciences – Integrated Diagnostic Solutions as well as its medication management solution.
On the sidelines of the show, Maher ElHassan, Vice President & General Manager, MENAT, BD, told us that the region’s healthcare industry was undergoing an unprecedented transformation, especially in the field of medical technology (MedTech). He said: “This is our first participation in a physical show since the pandemic began, and we are proud to be present and support the region.”
To provide continued support and expertise, BD has been working closely with stakeholders in the industry to understand their challenges and meet their needs by bringing the latest innovations to market. “We are looking to bring MedTech innovation in the areas of infection prevention and control, as well as rapid diagnostics, laboratory automation and cutting-edge research. This aligns with our mission of enhancing patient care and safety.”
BD Biosciences displayed products such as flow cytometry instruments for single-cell analysis for clinical and research applications at the show.
Mohamad Kurdi, PhD, Clinical Affairs Manager, Middle East & North Africa, BD Biosciences, said: “For clinical application, we have the latest generation of flow cytometry, which can be used alone or in combination with a pre-analytical system. Its main application is in the haematological laboratory, for instance, in the application for the diagnosis of lymphoma or leukaemia. The instrument was designed to respond to the needs of the clinical laboratory, especially in terms of standardisation and accreditation, which is mandatory in most countries. Moreover, it makes the life of a laboratory professional very easy as it’s fully automated and simple to use.”
While BD’s Integrated Diagnostic Solutions business provides assessment and management of microbiology solutions and it offers completely automated solutions for different clinical laboratory needs, right from blood culture to sepsis management. “We provide solutions that completely transform the microbiology laboratory,” said Dewanand Mahto, Clinical Development Manager, BD.
For example, when a sample comes to the laboratory, several steps must be carried out manually. But today, artificial intelligence (AI) is being used to read culture plates that can automatically tell if a result is positive or negative.
“We have molecular instruments with different assays that provide rapid and reliable results within two to three hours depending on the different solutions right from women’s health and cancer to tuberculosis,” Mahto explained.
Furthermore, for antimicrobial resistance (AMR), the company has specific solutions such as antibiotic panels that are being used only in this region. These offer rapid and reliable results and decrease the patient length of stay and reduce the cost of antibiotics.
“We are continuously working on improving the way we partner with the authorities and our existing distributors to offer the best solutions and cutting-edge technology to the market,” ElHassan concluded.
This article appears in the latest issue of Omnia Health Magazine. Read the full issue online today.
